



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Exercise Window Trial in Newly Diagnosed Breast Cancer - Letter

Citation for published version:

Sims, A, Leggate, M & Campbell, A 2019, 'Exercise Window Trial in Newly Diagnosed Breast Cancer - Letter', *Clinical Cancer Research*. <https://doi.org/10.1158/1078-0432.CCR-19-2571>

Digital Object Identifier (DOI):

[10.1158/1078-0432.CCR-19-2571](https://doi.org/10.1158/1078-0432.CCR-19-2571)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Clinical Cancer Research

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Exercise Window Trial in Newly Diagnosed Breast Cancer - Letter

Andrew H. Sims¹, Melanie Leggate², Anna Campbell²

¹Applied Bioinformatics of Cancer, University of Edinburgh Cancer Research UK Centre, Edinburgh, UK

²School of Applied Sciences, Edinburgh Napier University, Edinburgh, UK

We read with great interest the article by Ligibel and colleagues [1], of the Pre-Operative Health and Body (PreHAB) study looking at the molecular effects of exercise on breast tumours between diagnosis and surgery. The reported up-regulation of pathways related to inflammation and immunity is consistent with the expected role of the tumour microenvironment in response to exercise [2]. Sequentially-sampled window studies have great potential to inform by minimising patient-patient variation, but are a very challenging way to examine the effects of treatment or other interventions. Assessment of proliferation is a natural endpoint for response, but measurement of Ki67 is notoriously unreliable.

There are many different gene expression analysis approaches and numerous breast cancer signatures [3]. The current drive for reproducible research has led to expectations that datasets and analysis software are made freely available. With this in mind and our desire to perform similar studies, we reanalysed the PreHAB study gene expression data (GSE129508) using the GeneFu package [4] to calculate estimations of the established genomic grade index, PAM50 and Mammaprint risk of relapse prognosis prediction algorithms of the samples taken at diagnosis and excision from patients randomised to the exercise and control groups.

The majority of exercising patients (12/16) had significantly reduced predicted PAM50 risk of relapse scores ($p=0.03$), whereas half of the control group had smaller non-significant ($p=0.81$) reductions in predicted risk of relapse. Trends ($p=0.08$, $p=0.09$) for reductions in genomic grade index and Mammaprint scores in most exercising patients were not evident in controls (Figure 1). These prognostic signatures were derived from different analytical approaches and represent different facets of breast tumour biology including proliferation, immune response and oestrogen signalling.

Whole tumour gene expression profiling captures information on all cell types, whereas deconvolution approaches can generate *in silico* predictions of the proportions of immune cell types present in samples. As above, we used the ImSig package [5] to assess changes in immune cell content changes in the PreHAB data. Increases in several immune cell types were observed including macrophages and B-cells, alongside a reduction in proliferation, but these changes were not statistically significant.

Our analysis highlights different analysis approaches and supports the findings of the original study. We strongly encourage further studies in this area to examine the biological consequences of exercise on tumours along with assessments of the feasibility of introducing optimal and tolerable exercise regimens into routine clinical care for cancer patients.

References

- 1 Ligibel JA, Dillon D, Giobbie-Hurder A, *et al.* Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study. *Clin Cancer Res* April 2019
- 2 Zhang X, Ashcraft KA, Betof Warner A, *et al.* Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity? *Cancer Res* 2019; **79**: 2447-2456
- 3 Sims AH. Bioinformatics and breast cancer: what can high-throughput genomic approaches actually tell us? *J Clin Pathol* 2009; **62**: 879-885
- 4 Gendoo DMA, Ratanasirigulchai N, Schröder MS, *et al.* Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. *Bioinformatics* 2015; **32**: 1097-1099
- 5 Nirmal AJ, Regan T, Shih BB, *et al.* Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors. *Cancer Immunol Res* 2018; **6**: 1388-1400

Acknowledgements

AHS is grateful for funding from Breast Cancer Now and Cancer Research UK

Figure 1 Pre-surgical exercise improves predicted prognosis for breast cancer patients
Reductions in molecular signature scores are shown in blue and increases in red.

